Cardiovascular safety of therapies for type 2 diabetes

References

• Centers for Disease Control and Prevention (CDC). National diabetes statistics report [Internet]. Atlanta (GA): US Dep. Health Hum. Serv., Cent. Dis. Control Prevent; 2014. Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf
   Google Scholar
• Meigs JB. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta Diabetologica. 2003;40(Suppl. 2):S358–61.
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS-33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818–828.
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med. 2008;359:1092–1095.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. Silver Spring (MD): US Food and Drug Adm; 2008. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
   Google Scholar
• Scirica BM, Bhatt DI, Braunwald E, et al.; the SAVOR-TIMI53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al.; and the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
   PubMed Web of Science ®Google Scholar
• Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagon like peptide-17–36 amide and glucagon like peptide-17–37 in healthy subjects are indistinguishable. Diabetes. 1993;42:658–661.
   PubMed Web of Science ®Google Scholar
• Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585–3596.
   PubMed Web of Science ®Google Scholar
• Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51:501–514.
   PubMed Web of Science ®Google Scholar
• Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427–3434.
   PubMed Web of Science ®Google Scholar
• Kushner P. Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of type 2 diabetes. Womens Health. (Epub ahead of print). DOI:10.2217/whe-2016-0001
   Web of Science ®Google Scholar
• Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig. 2014;5:265–275.
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–965.
   PubMed Web of Science ®Google Scholar
• Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694–699.
   PubMed Web of Science ®Google Scholar
• Halbirk M, Nørrelund H, Møller N, et al. Cardiovascular and metabolic effects of 48-hour glucagon like peptide 1 infusion in compensated chronic heart failure patients. Am J Physiol Heart Circ Physiol. 2010;298:H1096–102.
   PubMedGoogle Scholar
• Løngborg J, Vijlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491–1499.
   PubMed Web of Science ®Google Scholar
• Lønborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST segment elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5:288–295.
   PubMed Web of Science ®Google Scholar
• Noyan-Ashraf MH, Shikatani EA, Schuiki I, et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127:74–85.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhong J, Lin H, et al. Blood pressure–lowering effects ofGLP-1receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diab Obes Metab. 2013;15:737–749.
   PubMed Web of Science ®Google Scholar
• Kotout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27:130–139.
   PubMed Web of Science ®Google Scholar
• Sauve M, Ban K, Momen A, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice. Diabetes. 2010;59:1063–1073.
   PubMed Web of Science ®Google Scholar
• Huisamen B, Genis A, Marais E, et al. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther. 2011;25:13–20.
   PubMed Web of Science ®Google Scholar
• McCormick LM, Kydd AC, Read PA, et al. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circ Cardiovasc Imaging. 2014;7:274–281.
   PubMed Web of Science ®Google Scholar
• Dos Santos L, Salles TA, Arruda-Junior EF, et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail. 2013;6:1029–1038.
   PubMed Web of Science ®Google Scholar
• Gomez N, Touihri K, Matheeussen V, et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14:14–21.
   PubMed Web of Science ®Google Scholar
• Takahashi A, Asakura M, Ito S, et al. Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. Am J Physiol Heart Circ Physiol. 2013;304:H1361–69.
   Google Scholar
• Terasaki M, Hiromura M, Mori Y, et al. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS One. 2015;10:e0143396.
   PubMed Web of Science ®Google Scholar
• Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148. DOI:10.1186/s12933-014-0148-1
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Haneda M, Inagaki N, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther. 2014;31:621–638.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Haneda M, Inagaki N, et al. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. Adv Ther. 2015;32:306–318.
   PubMed Web of Science ®Google Scholar
• Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208–219.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015–4021.
   PubMed Web of Science ®Google Scholar
• Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13:119–126.
   PubMed Web of Science ®Google Scholar
• Araki E, Tanizawa Y, Tanaka Y, et al. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:665–674.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154–1160.
   PubMed Web of Science ®Google Scholar
• Hu H, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650–1659.
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405–415.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403–411.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016 Jul;375(4):323–334.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–1588.
   PubMed Web of Science ®Google Scholar
• Gilbert TE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015;385:2107–2117.
   PubMed Web of Science ®Google Scholar
• Marney A, Kunchakarra S, Byrne L, et al. Interactive hemodynamic effects of dipeptidyl peptidase IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56:728–733.
   PubMed Web of Science ®Google Scholar
• White WB, Wilson CA, Bakris GL, et al. Angiotensin-converting enzyme inhibitor use and major cardiovascular outcomes in type 2 diabetes mellitus treated with the dipeptidyl dipeptidase 4 inhibitor alogliptin. Hypertension. 2016;68:606–613.
   Web of Science ®Google Scholar
• White WB, Baker WH. Cardiovascular effects of incretin-based therapies. Ann Rev Med. 2016;67:245–260.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicenter, randomized, double-blind trial. Lancet. 2015;385(9982):2067–2076.
   PubMed Web of Science ®Google Scholar
• Toh S, Hampp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin and other antihyperglycemic drugs. Ann Intern Med. 2016;164(11):705–714.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Avogaro A, Degli Esposti L, et al. Risk of hospitalization for heart failure in type 2 diabetes newly treated with DPP-4 inhibitors or other glucose lowering medications: a retrospective registry study on 127,555 patients from the nationwide OsMed Health-DB database. Eur Heart J. 2015;36:2454–2462.
   PubMed Web of Science ®Google Scholar
• Filion KB, Azoulay L, Platt RW, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374:1145–1154.
   PubMed Web of Science ®Google Scholar
• Li L, Sheyu L, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: a systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610.
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks n sulfonylurea treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–2635.
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatode (exendin-4) on glycemic control over 30 weeks in patents with type 2 diabetes treated with metformin and sulfonylurea. Diabetes Care. 2005;28:1083–1091.
   PubMed Web of Science ®Google Scholar
• Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448–1460.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, et al. Effects of exentide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–1100.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev. 2011;27:528–542.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of ype 2 diabetes: a randomized, open-label, noninferiority study. Lancet. 2008;372:1240–1250.
   PubMed Web of Science ®Google Scholar
• Zinman B, Hoogwerf BJ, Duran GS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146:477–485.
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559–569.
   PubMed Web of Science ®Google Scholar
• Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exentide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract. 2008;14:285–292.
   PubMedGoogle Scholar
• Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med. 2008;25:152–156.
   PubMed Web of Science ®Google Scholar
• Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide- the FDA’s review of a new antidiabetic therapy. N Engl J Med. 2010;62:774–777.
   Web of Science ®Google Scholar
• Knudsen L, Madsen LW, Andersen S, et al. Glucagon like peptide-1 receptor agonists activate rodent thyroid C- cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473–1486.
   PubMed Web of Science ®Google Scholar
• Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14:1061–1072.
   PubMed Web of Science ®Google Scholar
• Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258–267.
   PubMed Web of Science ®Google Scholar
• Lehrke M, Marx N, Patel S, et al. Safety and tolerability of Linagliptin in patients with type 2 diabetes: a comprehensive pooled analysis of 22 placebo-controlled studies. Clin Ther. 2014;36:1130–1146.
   PubMed Web of Science ®Google Scholar
• Salvo F, Moore N, Arnaud M, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ. 2016;353:i2231. DOI:10.1136/bmj.i2231
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206.
   PubMed Web of Science ®Google Scholar
• Singh S, Chang HY, Richards TM, et al. Glucagon like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173:534–539.
   PubMed Web of Science ®Google Scholar
• Tarapués M, Cereza G, Figueras A. Association of musculoskeletal complaints and gliptin use: review of spontaneous reports. Pharmacoepidemiol Drug Saf. 2013;22:1115–1118.
   PubMed Web of Science ®Google Scholar
• Chaicha-Brom T, Yasmeen T. DPP-IV inhibitor-associated arthralgias. Endocr Pract. 2013;19:377.
   PubMed Web of Science ®Google Scholar
• Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38(6):1299–1313.
   PubMed Web of Science ®Google Scholar
• Munir KM, Davis SN. Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes. Clin Pharmacol. 2016;8:19–34.
   PubMedGoogle Scholar
• Usiskin K, Kline I, Fung A, et al. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014;126:16–34.
   PubMed Web of Science ®Google Scholar
• Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147–158.
   PubMed Web of Science ®Google Scholar
• Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394–402.
   PubMed Web of Science ®Google Scholar
• Haering HU, Merker L, Christiansen AV, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;110:82–90.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815–1823.
   PubMed Web of Science ®Google Scholar
• Sinclair AJ, Bode B, Harris S, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc. 2016;64:543–552.
   PubMed Web of Science ®Google Scholar
• Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2015;101:157–166.
   PubMed Web of Science ®Google Scholar
• John M, Gopinath D, Jagesh R. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: clinical perspectives. Indian J Endocrinol Metab. 2016;20:22–31.
   PubMedGoogle Scholar
• Sager PT, Seltzer J, Turner JR, et al. Cardiovascular safety outcome trials: a meeting report from the cardiac safety research consortium. Am Heart J. 2015;169:486–95.
   PubMed Web of Science ®Google Scholar